Evidence map›Paper›PMID 33130858›Full record

ArticleNeuro-oncology2021

Radiological assessment schedule for high-grade glioma patients during the surveillance period using parametric modeling.

So Young Ji, Jongjin Lee, Joo Ho Lee, Soon-Tae Lee, Jae Kyung Won, Jin Wook Kim, Yong Hwy Kim, Tae Min Kim, Seung Hong Choi, Sung-Hye Park and 2 more

Abstract read
In one paragraph

Article in Neuro-oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Sarcopenia is associated with chemoradiotherapy discontinuation and reduced progression-free survival in glioblastoma patients.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2024
    Article
  6. Observational
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

So Young JiDepartment of Neurosurgery, Seoul National University Hospital, Seoul National University College of Medicine.
Jongjin LeeDepartment of Statistics, Seoul National University.
Joo Ho LeeDepartment of Radiation Oncology, Seoul National University Hospital.
Soon-Tae LeeDepartment of Neurology, Seoul National University Hospital.
Jae Kyung WonDepartment of Pathology, Seoul National University Hospital.
Jin Wook KimDepartment of Neurosurgery, Seoul National University Hospital, Seoul National University College of Medicine.
Yong Hwy KimDepartment of Neurosurgery, Seoul National University Hospital, Seoul National University College of Medicine.
Tae Min KimDepartment of Internal Medicine, Seoul National University Hospital.
Seung Hong ChoiDepartment of Radiology, Seoul National University Hospital.
Sung-Hye ParkDepartment of Pathology, Seoul National University Hospital.
Yongdai KimDepartment of Statistics, Seoul National University.
Chul-Kee ParkDepartment of Neurosurgery, Seoul National University Hospital, Seoul National University College of Medicine.ORCID 0000-0002-2350-9876

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAn optimal radiological surveillance plan is crucial for high-grade glioma (HGG) patients, which is determined arbitrarily in daily clinical practice. We propose the radiological assessment schedule using a parametric model of standardized progression-free survival (PFS) curves.

methodsA total of 277 HGG patients (178 glioblastoma [GBM] and 99 anaplastic astrocytoma [AA]) from a single institute who completed the standard treatment protocol were enrolled in this cohort study and retrospectively analyzed. The patients were stratified into each layered risk group by genetic signatures and residual mass or through recursive partitioning analysis. PFS curves were estimated using the piecewise exponential survival model. The criterion of a 10% progression rate among the remaining patients at each observation period was used to determine the optimal radiological assessment time point.

resultsThe optimal follow-up intervals for MRI evaluations of isocitrate dehydrogenase (IDH) wild-type GBM was every 7.4 weeks until 120 weeks after the end of standard treatment, followed by a 22-week inflection period and every 27.6 weeks thereafter. For the IDH mutated GBM, scans every 13.2 weeks until 151 weeks are recommended. The optimal follow-up intervals were every 22.8 weeks for IDH wild-type AA, and 41.2 weeks for IDH mutated AA until 241 weeks. Tailored radiological assessment schedules were suggested for each layered risk group of the GBM and the AA patients.

conclusionsThe optimal schedule of radiological assessments for each layered risk group of patients with HGG could be determined from the parametric model of PFS.

Indexed as

Brain NeoplasmsGliomaCohort StudiesHumansIsocitrate DehydrogenaseRetrospective StudiesIsocitrate Dehydrogenasefollow-upglioblastomahigh-grade gliomaMRI scheduleparametric model

Identifiers

PMID33130858
PMCPMC8099465

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.